<DOC>
	<DOCNO>NCT02051868</DOCNO>
	<brief_summary>Anal cancer relatively uncommon disease currently standard chemotherapy treatment patient inoperable locally recurrent metastatic disease . The aim phase II study compare two well know largely used chemotherapy regimens - Cisplatin plus 5-fluorouracil v Carboplatin plus Paclitaxel . The result study set standard care disease provide useful information future Phase III trial .</brief_summary>
	<brief_title>International Multicentre Study Advanced Anal Cancer Comparing Cisplatin Plus 5 FU v Carboplatin Plus Weekly Paclitaxel</brief_title>
	<detailed_description>Study design : This international , multicentre , open label , randomise phase II trial . Patients randomise receive either cisplatin plus 5-FU carboplatin plus weekly paclitaxel . Region ( Europe , North America , South America &amp; Australia ) , ( Eastern Cooperative Oncology Group- ECOG ) ECOG performance status ( PS ) ( 0-1 vs. 2 ) , HIV status ( positive vs. negative ) extent disease ( locally recurrent vs. metastatic ) use stratification factor . Overall response rate primary endpoint . Indication : First line treatment patient inoperable locally recurrent metastatic squamous cell carcinoma anus . Length study : Recruitment complete within 3 year . The estimated recruitment rate 4-6 patient per month establish multiple centre . Primary Objective : To evaluate best overall response rate 24 week post treatment cisplatin plus 5-fluorouracil arm versus carboplatin plus weekly paclitaxel arm Secondary Objectives : To evaluate : - Progression-free survival - Overall survival - Disease control rate ( stable disease well ) 12 24 week - Best overall response metastatic lesion - Toxicity ( grade accord National Cancer Institute Common Terminology Criteria Adverse Events ( NCI CTCAE Version 4 ) - Quality Life ( use EORTC QLQ-C30 version 3 EQ-5D-5L questionnaire ) . To assess : The feasibility conduct multicentre international study squamous cell carcinoma anus recruit within reasonable time frame . Exploratory Objective : Explorative biomarker analysis include collection archive tumour tissue blood sample baseline upon progression .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Anus Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Inclusion Criteria 1 . Histologically cytologically verify , unidimensionally measurable , inoperable , locally recurrent metastatic squamous cell carcinoma anus . 2 . Age ≥18 year . 3 . ECOG Performance status ≤2 . 4 . Measurable disease accord Response Evaluation Criteria Solid Tumours ( RECIST ) criteria version 1.1 . 5 . Previous definitive chemoradiotherapy permit early stage squamous cell carcinoma anus . 6 . HIV+ patient consider eligible CD4 count ≥200 . 7 . Adequate cardiac respiratory function ; absolute neutrophil count ( ANC ) ≥1.5x10^9/l ; white blood cell ( WBC ) count ≥3x10^9/l ; platelet &gt; 100x10^9/l ; haemoglobin ( Hb ) ≥9g/dl ; creatinine clearance &gt; 50ml/minute ; serum bilirubin ≤1.5x upper limit normal ( ULN ) ; alanine transaminase ( ALT ) /aspartate transaminase ( AST ) ≤2.5x ULN ; alkaline phosphatase ( ALP ) ≤3x ULN . 8 . Fertile men woman must agree take adequate contraceptive precaution , least six month therapy . 9 . Life expectancy least 3 month . Exclusion Criteria 1 . Tumours adenocarcinoma , melanoma , small cell basal cell histology exclude . 2 . Previous chemotherapy , radiotherapy investigational drug surgically unresectable locally recurrent advance squamous cell carcinoma anus 3 . Current recent ( within 30 day first study dose ) treatment another investigational drug participation another investigational study . 4 . Documented symptomatic brain metastasis and/or central nervous system metastases leptomeningeal disease . 5 . Surgery palliative radiotherapy within 28 day randomisation . 6 . Clinically significant ( i.e . active ) cardiac disease ( e.g . symptomatic coronary artery disease , uncontrolled cardiac arrhythmia , myocardial infarction within last 6 month ) . Any history clinically significant cardiac failure . 7 . History interstitial lung disease ( e.g . pneumonitis pulmonary fibrosis ) evidence interstitial lung disease baseline chest CT scan . 8 . Lack physical integrity gastrointestinal tract , malabsorption syndrome ( nasogastric jejunostomy feed tube permit ) . 9 . Acute hepatitis C and/or chronic active hepatitis B infection . 10 . Serious active infection require i.v . antibiotic enrolment . 11 . Other malignancy within last 5 year , except adequately treat carcinoma situ cervix squamous carcinoma skin , adequately control limited basal cell skin cancer . 12 . Other clinically significant disease comorbidity may adversely affect safe delivery treatment within trial . 13 . Known hypersensitivity study drug excipients . 14 . Known peripheral neuropathy ≥ grade 1 ( absence deep tendon reflexes sole neurological abnormality render patient ineligible ) . 15 . Preexisting hear impairment . 16 . Patients plan live vaccine . 17 . Pregnant lactating female .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Squamous cell carcinoma anus</keyword>
	<keyword>Anal cancer</keyword>
	<keyword>Cancer anus</keyword>
	<keyword>SCCA</keyword>
	<keyword>Cisplatin-5FU</keyword>
	<keyword>Carboplatin-Paclitaxel</keyword>
	<keyword>inoperable</keyword>
	<keyword>locally recurrent</keyword>
	<keyword>metastatic</keyword>
</DOC>